Drug Profile
Research programme: autotaxin inhibitors - Gilead Sciences/X-Rx Discovery
Alternative Names: ATX inhibitors - X-Rx DiscoveryLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator X-Rx
- Developer Gilead Sciences
- Class Antifibrotics; Small molecules
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis